Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Cellular Oncology
Published in: Cellular Oncology 4/2018

01-08-2018 | Review

Mutual concessions and compromises between stromal cells and cancer cells: driving tumor development and drug resistance

Authors: Pritish Nilendu, Sachin C. Sarode, Devashree Jahagirdar, Ishita Tandon, Shankargouda Patil, Gargi S. Sarode, Jayanta K. Pal, Nilesh Kumar Sharma

Published in: Cellular Oncology | Issue 4/2018

Login to get access

Abstract

Background

Various cancers have been found to be associated with heterogeneous and adaptive tumor microenvironments (TMEs) and to be driven by the local TMEs in which they thrive. Cancer heterogeneity plays an important role in tumor cell survival, progression and drug resistance. The diverse cellular components of the TME may include cancer-associated fibroblasts, adipocytes, pericytes, mesenchymal stem cells, endothelial cells, lymphocytes and other immune cells. These components may support tumor development through the secretion of growth factors, evasion from immune checkpoints, metabolic adaptations, modulations of the extracellular matrix, activation of oncogenes and the acquisition of drug resistance. Here, we will address recent advances in our understanding of the molecular mechanisms underlying stromal-tumor cell interactions, with special emphasis on basic and pre-clinical information that may facilitate the design of novel personalized cancer therapies.

Conclusions

This review presents a holistic view on the translational potential of the interplay between stromal cells and cancer cells. This interplay is currently being employed for the development of promising preclinical and clinical biomarkers, and the design of small molecule inhibitors, antibodies and small RNAs for (combinatorial) cancer treatment options. In addition, nano-carriers, tissue scaffolds and 3-D based matrices are being developed to precisely and safely deliver these compounds.
Literature
1.
M. Plummer, C. de Martel, J. Vignat, J. Ferlay, F. Bray, S. Franceschi, Global burden of cancers attributable to infections in 2012: A synthetic analysis. Lancet Glob. Health 4, e609–e616 (2016)CrossRef
2.
3.
4.
A.A. Alizadeh, V. Aranda, A. Bardelli, C. Blanpain, C. Bock, C. Borowski, C. Caldas, A. Califano, M. Doherty, M. Elsner, M. Esteller, R. Fitzgerald, J.O. Korbel, P. Lichter, C.E. Mason, N. Navin, D. Peer, K. Polyak, C.W.M. Roberts, L. Siu, A. Snyder, H. Stower, C. Swanton, R.G.W. Verhaak, J.C. Zenklusen, J. Zuber, J. Zucman-Rossi, Toward understanding and exploiting tumor heterogeneity. Nat. Med. 21, 846–853 (2015)PubMedPubMedCentralCrossRef
5.
J.W. Clark, B.A. Chabner, Limits to precision cancer medicine. N. Engl. J. Med. 376, 95–97 (2017)CrossRef
6.
L.A. Liotta, E.C. Kohn, The microenvironment of the tumour host interface. Nature 411, 375–379 (2001)PubMedCrossRef
7.
8.
J.W. Pollard, Tumour-educated macrophages promote tumour progression and metastasis. Nat. Rev. Cancer 4, 71–78 (2004)PubMedCrossRef
9.
V. Kumar, L. Donthireddy, D. Marvel, T. Condamine, F. Wang, S. Lavilla-Alonso, A. Hashimoto, P. Vonteddu, R. Behera, M.A. Goins, C. Mulligan, B. Nam, N. Hockstein, F. Denstman, S. Shakamuri, D.W. Speicher, A.T. Weeraratna, T. Chao, R.H. Vonderheide, L.R. Languino, P. Ordentlich, Q. Liu, X. Xu, A. Lo, E. Puré, C. Zhang, A. Loboda, M.A. Sepulveda, L.A. Snyder, D.I. Gabrilovich, Cancer-associated fibroblasts neutralize the anti-tumor effect of CSF1 receptor blockade by inducing PMN-MDSC infiltration of tumors. Cancer Cell 32 e655, 654–668 (2017)
10.
Y. Qiao, C. Zhang, A. Li, D. Wang, Z. Luo, Y. Ping, B. Zhou, S. Liu, H. Li, D. Yue, Z. Zhang, X. Chen, Z. Shen, J. Lian, Y. Li, S. Wang, F. Li, L. Huang, L. Wang, B. Zhang, J. Yu, Z. Qin, Y. Zhang, IL6 derived from cancer-associated fibroblasts promotes chemoresistance via CXCR7 in esophageal squamous cell carcinoma. Oncogene 37, 873–883 (2017). https://​doi.​org/​10.​1038/​onc.​2017.​387 PubMedCrossRef
11.
H.G. Augustin, G.Y. Koh, Organotypic vasculature: From descriptive heterogeneity to functional pathophysiology. Science 357, eaal2379 (2017)PubMedCrossRef
12.
M. Spaw, S. Anant, S.M. Thomas, Stromal contributions to the carcinogenic process. Mol. Carcinog. 56, 1199–1213 (2017)PubMedCrossRef
13.
14.
M. Cheng, S. Ho, J.H. Yoo, D.H. Tran, K. Bakirtzi, B. Su, D.H. Tran, Y. Kubota, R. Ichikawa, H.W. Koon, Cathelicidin suppresses colon cancer development by inhibition of cancer associated fibroblasts. Clin. Exp. Gastroenterol. 8, 13–29 (2015)PubMed
15.
V. Gkretsi, A. Stylianou, P. Papageorgis, C. Polydorou, T. Stylianopoulos, Remodeling components of the tumor microenvironment to enhance cancer therapy. Front. Oncol. 5, 214 (2015)
16.
D. Jahagirdar, S. Purohit, A. Jain, N.K. Sharma, Export of microRNAs: A bridge between breast carcinoma and their neighboring cells. Front. Oncol. 6, 147 (2016)
17.
M. Najar, H. Fayyad-Kazan, W.H. Faour, B. Badran, F. Journe, L. Lagneaux, Breast cancer cells and bone marrow mesenchymal stromal cells: A regulated modulation of the breast tumor in the context of immune response. Inflamm. Res. 66, 129–139 (2017)PubMedCrossRef
18.
P. Nilendu, A. Kumar, A. Kumar, J.K. Pal, N.K. Sharma, Breast cancer stem cells as last soldiers eluding therapeutic burn: A hard nut to crack. Int. J. Cancer 142, 7–17 (2017)PubMedCrossRef
19.
R. Kalluri, The biology and function of fibroblasts in cancer. Nat. Rev. Cancer 16, 582–598 (2016)PubMedCrossRef
20.
P.J. Morin, in Cancer Drug Resistance, ed. by B.A. Teicher (Humana Press, Totowa, NJ, 2006), pp. 201–210
21.
A. Morandi, E. Giannoni, P. Chiarugi, Nutrient exploitation within the tumor–stroma metabolic crosstalk. Trends Cancer 2, 736–746 (2016)PubMedCrossRef
22.
K. Cyll, E. Ersvær, L. Vlatkovic, M. Pradhan, W. Kildal, M.A. Kjær, A. Kleppe, T.S. Hveem, B. Carlsen, S. Gill, S. Löffeler, E.S. Haug, H. Wæhre, P. Sooriakumaran, H.E. Danielsen, Tumour heterogeneity poses a significant challenge to cancer biomarker research. Br. J. Cancer 117, 367–375 (2017)PubMedPubMedCentralCrossRef
23.
M. Majidinia, B. Yousefi, Breast tumor stroma: A driving force in the development of resistance to therapies. Chem. Biol. Drug Des. 89, 309–318 (2017)PubMedCrossRef
24.
N. McGranahan, C. Swanton, Clonal heterogeneity and tumor evolution: Past, present, and the future. Cell 168, 613–628 (2017)PubMedCrossRef
25.
N. Picco, E. Sahai, P.K. Maini, A.R.A. Anderson, Integrating models to quantify environment-mediated drug resistance. Cancer Res. 77, 5409–5418 (2017)PubMedCrossRef
26.
27.
A.L. Ribeiro, O.K. Okamoto, Combined effects of pericytes in the tumor microenvironment. Stem Cells Int. 868475, 2015 (2015)
28.
C.C. Maley, A. Aktipis, T.A. Graham, A. Sottoriva, A.M. Boddy, Classifying the evolutionary and ecological features of neoplasms. Nat. Rev. Cancer 17, 605–619 (2017)PubMedPubMedCentralCrossRef
29.
H. Omar Al-Hassi, O. Ng, M. Brookes, Tumour-associated and non-tumour-associated microbiota in colorectal cancer. Gut 67, 395 (2018)PubMedCrossRef
30.
31.
Z. Benyahia, N. Dussault, M. Cayol, R. Sigaud, C. Berenguer-Daize, C. Delfino, A. Tounsi, S. Garcia, P.M. Martin, K. Mabrouk, L. Ouafik, Stromal fibroblasts present in breast carcinomas promote tumor growth and angiogenesis through adrenomedullin secretion. Oncotarget 8, 15744–15762 (2017)PubMedPubMedCentralCrossRef
32.
L. Bolm, S. Cigolla, U.A. Wittel, U.T. Hopt, T. Keck, D. Rades, P. Bronsert, U.F. Wellner, The role of fibroblasts in pancreatic cancer: Extracellular matrix versus paracrine factors. Transl. Oncol. 10, 578–588 (2017)PubMedPubMedCentralCrossRef
33.
N. Cohen, O. Shani, Y. Raz, Y. Sharon, D. Hoffman, L. Abramovitz, N. Erez, Fibroblasts drive an immunosuppressive and growth-promoting microenvironment in breast cancer via secretion of Chitinase 3-like 1. Oncogene 36, 4457–4468 (2017)PubMedPubMedCentralCrossRef
34.
35.
A. Aboussekhra, Role of cancer-associated fibroblasts in breast cancer development and prognosis. Int. J. Dev. Biol. 55, 841–849 (2011)PubMedCrossRef
36.
U.M. Polanska, A. Orimo, Carcinoma-associated fibroblasts: Non-neoplastic tumour-promoting mesenchymal cells. J. Cell. Physiol. 228, 1651–1657 (2013)PubMedCrossRef
37.
H. Luo, G. Tu, Z. Liu, M. Liu, Cancer-associated fibroblasts: A multifaceted driver of breast cancer progression. Cancer Lett. 361, 155–163 (2015)PubMedCrossRef
38.
A. Orimo, R.A. Weinberg, Stromal fibroblasts in cancer: A novel tumor-promoting cell type. Cell Cycle 5, 1597–1601 (2006)PubMedCrossRef
39.
G.S. Markopoulos, E. Roupakia, M. Tokamani, E. Chavdoula, M. Hatziapostolou, C. Polytarchou, K.B. Marcu, A.G. Papavassiliou, R. Sandaltzopoulos, E. Kolettas, A step-by-step microRNA guide to cancer development and metastasis. Cell. Oncol. 40, 303–339 (2017)CrossRef
40.
P. Mishra, D. Banerjee, A. Ben-Baruch, Chemokines at the crossroads of tumor-fibroblast interactions that promote malignancy. J. Leukoc. Biol. 89, 31–39 (2011)PubMedCrossRef
41.
K.O. Osuala, M. Sameni, S. Shah, N. Aggarwal, M.L. Simonait, O.E. Franco, Y. Hong, S.W. Hayward, F. Behbod, R.R. Mattingly, B.F. Sloane, Il-6 signaling between ductal carcinoma in situ cells and carcinoma-associated fibroblasts mediates tumor cell growth and migration. BMC Cancer 15, 584 (2015)PubMedPubMedCentralCrossRef
42.
Ö. Sağlam, Z.S. Ünal, C. Subaşı, E. Ulukaya, E. Karaöz, IL-6 originated from breast cancer tissue-derived mesenchymal stromal cells may contribute to carcinogenesis. Tumour Biol. 36, 5667–5677 (2015)PubMedCrossRef
43.
D. von Ahrens, T.D. Bhagat, D. Nagrath, A. Maitra, A. Verma, The role of stromal cancer-associated fibroblasts in pancreatic cancer. J. Hematol. Oncol. 10, 76 (2017)
44.
S.-F. Hendrayani, H.H. Al-Khalaf, A. Aboussekhra, The cytokine IL-6 reactivates breast stromal fibroblasts through transcription factor STAT3-dependent up-regulation of the RNA-binding protein AUF1. J. Biol. Chem. 289, 30962–30976 (2014)PubMedPubMedCentralCrossRef
45.
T. Ishimoto, K. Miyake, T. Nandi, M. Yashiro, N. Onishi, K.K. Huang, S.J. Lin, R. Kalpana, S.T. Tay, Y. Suzuki, B.C. Cho, D. Kuroda, K. Arima, D. Izumi, M. Iwatsuki, Y. Baba, E. Oki, M. Watanabe, H. Saya, K. Hirakawa, H. Baba, P. Tan, Activation of transforming growth factor beta 1 signaling in gastric cancer-associated fibroblasts increases their motility, via expression of rhomboid 5 homolog 2, and ability to induce invasiveness of gastric cancer cells. Gastroenterology 153, 191-204. e116 (2017), 204.e16
46.
E. Sjöberg, M. Augsten, J. Bergh, K. Jirström, A. Östman, Expression of the chemokine CXCL14 in the tumour stroma is an independent marker of survival in breast cancer. Br. J. Cancer 114, 1117–1124 (2016)PubMedPubMedCentralCrossRef
47.
M. Yao, E. Yu, V. Staggs, F. Fan, N. Cheng, Elevated expression of chemokine C-C ligand 2 in stroma is associated with recurrent basal-like breast cancers. Mod. Pathol. 29, 810–823 (2016)PubMedCrossRef
48.
L. Zhao, G. Ji, X. Le, Z. Luo, C. Wang, M. Feng, L. Xu, Y. Zhang, W.B. Lau, B. Lau, Y. Yang, L. Lei, H. Yang, Y. Xuan, Y. Chen, X. Deng, T. Yi, S. Yao, X. Zhao, Y. Wei, S. Zhou, An integrated analysis identifies STAT4 as a key regulator of ovarian cancer metastasis. Oncogene 36, 3384–3396 (2017)PubMedCrossRef
49.
N. Kramer, J. Schmöllerl, C. Unger, H. Nivarthi, A. Rudisch, D. Unterleuthner, M. Scherzer, A. Riedl, M. Artaker, I. Crncec, D. Lenhardt, T. Schwarz, B. Prieler, X. Han, M. Hengstschläger, J. Schüler, R. Eferl, R. Moriggl, W. Sommergruber, H. Dolznig, Autocrine WNT2 signaling in fibroblasts promotes colorectal cancer progression. Oncogene 36, 5460–5472 (2017)PubMedCrossRef
50.
A. Avgustinova, M. Iravani, D. Robertson, A. Fearns, Q. Gao, P. Klingbeil, A.M. Hanby, V. Speirs, E. Sahai, F. Calvo, C.M. Isacke, Tumour cell-derived Wnt7a recruits and activates fibroblasts to promote tumour aggressiveness. Nat. Commun. 7, 10305 (2016)PubMedPubMedCentralCrossRef
51.
J.S.K. Chan, M.K. Sng, Z.Q. Teo, H.C. Chong, J.S. Twang, N.S. Tan, Targeting nuclear receptors in cancer-associated fibroblasts as concurrent therapy to inhibit development of chemoresistant tumors. Oncogene 37, 160–173 (2017)PubMedPubMedCentralCrossRef
52.
M.P. Pinto, W.W. Dye, B.M. Jacobsen, K.B. Horwitz, Malignant stroma increases luminal breast cancer cell proliferation and angiogenesis through platelet-derived growth factor signaling. BMC Cancer 14, 735 (2014)
53.
Y. Kitadai, T. Sasaki, T. Kuwai, T. Nakamura, C.D. Bucana, S.R. Hamilton, I.J. Fidler, Expression of activated platelet-derived growth factor receptor in stromal cells of human colon carcinomas is associated with metastatic potential. Int. J. Cancer 119, 2567–2574 (2006)PubMedCrossRef
54.
S. Neri, T. Miyashita, H. Hashimoto, Y. Suda, M. Ishibashi, H. Kii, H. Watanabe, T. Kuwata, M. Tsuboi, K. Goto, T. Menju, M. Sonobe, H. Date, A. Ochiai, G. Ishii, Fibroblast-led cancer cell invasion is activated by epithelial–mesenchymal transition through platelet-derived growth factor BB secretion of lung adenocarcinoma. Cancer Lett. 395, 20–30 (2017)PubMedCrossRef
55.
P.S.H. Soon, E. Kim, C.K. Pon, A.J. Gill, K. Moore, A.J. Spillane, D.E. Benn, R.C. Baxter, Breast cancer-associated fibroblasts induce epithelial-to-mesenchymal transition in breast cancer cells. Endocr. Relat. Cancer 20, 1–12 (2013)PubMedCrossRef
56.
A. Orimo, P.B. Gupta, D.C. Sgroi, F. Arenzana-Seisdedos, T. Delaunay, R. Naeem, V.J. Carey, A.L. Richardson, R.A. Weinberg, Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell 121, 335–348 (2005)PubMedCrossRef
57.
N.L.E. Harris, C. Vennin, J.R.W. Conway, K.L. Vine, M. Pinese, M.J. Cowley, R.F. Shearer, M.C. Lucas, D. Herrmann, A.H. Allam, M. Pajic, J.P. Morton, A.V. Biankin, M. Ranson, P. Timpson, D.N. Saunders, SerpinB2 regulates stromal remodelling and local invasion in pancreatic cancer. Oncogene 36, 4288–4298 (2017)PubMedPubMedCentralCrossRef
58.
N. Perurena, C. Zandueta, S. Martínez-Canarias, H. Moreno, S. Vicent, A.S. Almeida, E. Guruceaga, R.R. Gomis, M. Santisteban, M. Egeblad, EPCR promotes breast cancer progression by altering SPOCK1/testican 1-mediated 3D growth. J. Hematol. Oncol. 10, 23 (2017)PubMedPubMedCentralCrossRef
59.
S. Busch, A. Acar, Y. Magnusson, P. Gregersson, L. Ryden, G. Landberg, TGF-beta receptor type-2 expression in cancer-associated fibroblasts regulates breast cancer cell growth and survival and is a prognostic marker in pre-menopausal breast cancer. Oncogene 34, 27–38 (2015)PubMedCrossRef
60.
A.M. Hammer, G.M. Sizemore, V.C. Shukla, A. Avendano, S.T. Sizemore, J.J. Chang, R.D. Kladney, M.C. Cuitiño, K.A. Thies, Q. Verfurth, A. Chakravarti, L.D. Yee, G. Leone, J.W. Song, S.N. Ghadiali, M.C. Ostrowski, Stromal PDGFR-α activation enhances matrix stiffness, impedes mammary ductal development, and accelerates tumor growth. Neoplasia 19, 496–508 (2017)PubMedPubMedCentralCrossRef
61.
Y. Kinugasa, T. Matsui, N. Takakura, CD44 expressed on cancer-associated fibroblasts is a functional molecule supporting the stemness and drug resistance of malignant cancer cells in the tumor microenvironment. Stem Cells 32, 145–156 (2014)PubMedCrossRef
62.
B.Y. Owusu, S. Thomas, P. Venukadasula, Z. Han, J.W. Janetka, R.A. Galemmo Jr., L. Klampfer, Targeting the tumor-promoting microenvironment in MET-amplified NSCLC cells with a novel inhibitor of pro-HGF activation. Oncotarget 8, 63014–63025 (2017)PubMedPubMedCentralCrossRef
63.
J. Paulsson, L. Rydén, C. Strell, O. Frings, N.P. Tobin, T. Fornander, J. Bergh, G. Landberg, O. Stål, A. Östman, High expression of stromal PDGFRβ is associated with reduced benefit of tamoxifen in breast cancer. J. Pathol. Clin. Res. 3, 38–43 (2016)PubMedPubMedCentralCrossRef
64.
C.A.S. Corsa, A. Brenot, W.R. Grither, S. Van Hove, A.J. Loza, K. Zhang, S.M. Ponik, Y. Liu, D.G. DeNardo, K.W. Eliceiri, P.J. Keely, G.D. Longmore, The action of discoidin domain receptor 2 in basal tumor cells and stromal cancer-associated fibroblasts is critical for breast cancer metastasis. Cell Rep. 15, 2510–2523 (2016)PubMedPubMedCentralCrossRef
65.
X. Li, W. Zhu, Z. Chen, L. Luo, J. Huang, F. Zhang, M. Li, Y. Guo, L. Guo, Fibroblast growth factor-inducible 14 regulates cell growth and multidrug resistance of small-cell lung cancer through the nuclear factor-κB pathway. Anti-Cancer Drugs 25, 1152–1164 (2014)PubMedCrossRef
66.
E.M. De Francesco, A.H. Sims, M. Maggiolini, F. Sotgia, M.P. Lisanti, R.B. Clarke, GPER mediates the angiocrine actions induced by IGF1 through the HIF-1alpha/VEGF pathway in the breast tumor microenvironment. Breast Cancer Res. 19, 129 (2017)PubMedPubMedCentralCrossRef
67.
S.Y. Yeo, S.Y. Ha, K.W. Lee, Y. Cui, Z.T. Yang, Y.H. Xuan, S.H. Kim, Twist1 is highly expressed in cancer-associated fibroblasts of esophageal squamous cell carcinoma with a prognostic significance. Oncotarget 8, 65265–65280 (2017)PubMedPubMedCentralCrossRef
68.
D.E. Kim, M.-G. Procopio, S. Ghosh, S.-H. Jo, S. Goruppi, F. Magliozzi, P. Bordignon, V. Neel, P. Angelino, G.P. Dotto, Convergent roles of ATF3 and CSL in chromatin control of cancer-associated fibroblast activation. J. Exp. Med. 214, 2349–2368 (2017)PubMedPubMedCentralCrossRef
69.
W.N. Brennen, D.M. Rosen, H. Wang, J.T. Isaacs, S.R. Denmeade, Targeting carcinoma-associated fibroblasts within the tumor stroma with a fibroblast activation protein-activated prodrug. J. Natl. Cancer Inst. 104, 1320–1334 (2012)PubMedPubMedCentralCrossRef
70.
U.E. Martinez-Outschoorn, M.P. Lisanti, F. Sotgia, Catabolic cancer-associated fibroblasts transfer energy and biomass to anabolic cancer cells, fueling tumor growth. Semin. Cancer Biol. 25, 47–60 (2014)PubMedCrossRef
71.
B.B. Patel, E. Ackerstaff, I.S. Serganova, J.E. Kerrigan, R.G. Blasberg, J.A. Koutcher, D. Banerjee, Tumor stroma interaction is mediated by monocarboxylate metabolism. Exp. Cell Res. 352, 20–33 (2017)PubMedPubMedCentralCrossRef
72.
B. Chiavarina, D. Whitaker-Menezes, U.E. Martinez-Outschoorn, A.K. Witkiewicz, R. Birbe, A. Howell, R.G. Pestell, J. Smith, R. Daniel, F. Sotgia, M.P. Lisanti, Pyruvate kinase expression (PKM1 and PKM2) in cancer-associated fibroblasts drives stromal nutrient production and tumor growth. Cancer Biol. Ther. 12, 1101–1113 (2011)PubMedPubMedCentralCrossRef
73.
F. Lopes-Coelho, S. Andre, A. Felix, J. Serpa, Breast cancer metabolic cross-talk: Fibroblasts are hubs and breast cancer cells are gatherers of lipids. Mol. Cell. Endocrinol. 462, 93–106 (2018)PubMedCrossRef
74.
X. Tang, Y. Hou, G. Yang, X. Wang, S. Tang, Y.E. Du, L. Yang, T. Yu, H. Zhang, M. Zhou, S. Wen, L. Xu, M. Liu, Stromal miR-200s contribute to breast cancer cell invasion through CAF activation and ECM remodeling. Cell Death Differ. 23, 132–145 (2016)
75.
Y. Liu, J. Zhang, X. Sun, Q. Su, C. You, Down-regulation of miR-29b in carcinoma associated fibroblasts promotes cell growth and metastasis of breast cancer. Oncotarget 8, 39559–39570 (2017)PubMedPubMedCentral
76.
C.J. Clarke, T.J. Berg, J. Birch, D. Ennis, L. Mitchell, C. Cloix, A. Campbell, D. Sumpton, C. Nixon, K. Campbell, V.L. Bridgeman, P.B. Vermeulen, S. Foo, E. Kostaras, J.L. Jones, L. Haywood, E. Pulleine, H. Yin, D. Strathdee, O. Sansom, K. Blyth, I. McNeish, S. Zanivan, A.R. Reynolds, J.C. Norman, The initiator methionine tRNA drives secretion of type II collagen from stromal fibroblasts to promote tumor growth and angiogenesis. Curr. Biol. 26, 755–765 (2016)PubMedPubMedCentralCrossRef
77.
K.H. Vousden, Lane D.P. p53 in health and disease. Nat. Rev. 8, 275–283 (2007)CrossRef
78.
79.
M.S. Song, L. Salmena, P.P. Pandolfi, The functions and regulation of the PTEN tumour suppressor. Nat. Rev. Mol. Cell Biol. 13, 283–296 (2012)PubMedCrossRef
80.
M.G. Procopio, C. Laszlo, D. Al Labban, D.E. Kim, P. Bordignon, S.H. Jo, S. Goruppi, E. Menietti, Combined CSL and p53 downregulation promotes cancer-associated fibroblast activation. Nat. Cell Biol. 17, 1193–1204 (2015)PubMedPubMedCentralCrossRef
81.
P. Dauer, X. Zhao, V.K. Gupta, N. Sharma, K. Kesh, P. Gnamlin, Inactivation of Cancer-associated-fibroblasts disrupts oncogenic signaling in pancreatic Cancer cells and promotes its regression. Cancer Res. 78, 1321–1333 (2018)PubMedCrossRef
82.
Y. Hayashi, M. Tsujii, T. Kodama, T. Akasaka, J. Kondo, H. Hikita, T. Inoue, p53 functional deficiency in human colon cancer cells promotes fibroblast-mediated angiogenesis and tumor growth. Carcinogenesis 37, 972–984 (2016)PubMedCrossRef
83.
J.O. Schmid, M. Dong, S. Haubeiss, G. Friedel, S. Bode, A. Grabner, G. Ott, T.E. Mürdter, Cancer cells cue the p53 response of cancer-associated fibroblasts to cisplatin. Cancer Res. 72, 5824–5832 (2012)PubMedCrossRef
84.
C.P. Liao, H. Adisetiyo, M. Liang, P. Roy-Burman, Cancer-associated fibroblasts enhance the gland-forming capability of prostate cancer stem cells. Cancer Res. 70, 7294–7303 (2010)PubMedPubMedCentralCrossRef
85.
A.J. Trimboli, C.Z. Cantemir-Stone, F. Li, J.A. Wallace, A. Merchant, N. Creasap, Pten in stromal fibroblasts suppresses mammary epithelial tumors. Nature 461, 1084–1091 (2009)PubMedPubMedCentralCrossRef
86.
G.M. Sizemore, H.A.M. Balakrishnan, K.A. Thies, A.J. Trimboli, J.A. Wallace, Stromal PTEN inhibits the expansion of mammary epithelial stem cells through Jagged-1. Oncogene 36, 2297–2308 (2017)PubMedCrossRef
87.
88.
L. Bochet, C. Lehuede, S. Dauvillier, Y.Y. Wang, B. Dirat, V. Laurent, C. Dray, R. Guiet, I. Maridonneau-Parini, S. Le Gonidec, B. Couderc, G. Escourrou, P. Valet, C. Muller, Adipocyte-derived fibroblasts promote tumor progression and contribute to the desmoplastic reaction in breast cancer. Cancer Res. 73, 5657–5668 (2013)PubMedCrossRef
89.
K.M. Nieman, I.L. Romero, B. Van Houten, E. Lengyel, Adipose tissue and adipocytes support tumorigenesis and metastasis. Biochim. Biophys. Acta 1831, 1533–1541 (2013)
90.
J. Zhang, L. Zhang, C. Li, C. Yang, L. Li, S. Song, H. Wu, F. Liu, L. Wang, J. Gu, LOX-1 is a poor prognostic indicator and induces epithelial-mesenchymal transition and metastasis in pancreatic cancer patients. Cell. Oncol. 41, 73–84 (2018)CrossRef
91.
Y. Lee, W.H. Jung, J.S. Koo, Adipocytes can induce epithelial-mesenchymal transition in breast cancer cells. Breast Cancer Res. Treat. 153, 323–335 (2015)PubMedCrossRef
92.
C.-K. Huang, P.-H. Chang, W.-H. Kuo, C.-L. Chen, Y.-M. Jeng, K.-J. Chang, J.-Y. Shew, C.-M. Hu, W.-H. Lee, Adipocytes promote malignant growth of breast tumours with monocarboxylate transporter 2 expression via β-hydroxybutyrate. Nat. Commun. 8, 14706 (2017)
93.
Z. Jia, Y. Liu, S. Cui, Adiponectin induces breast cancer cell migration and growth factor expression. Cell Biochem. Biophys. 70, 1239–1245 (2014)PubMedCrossRef
94.
A. Yao-Borengasser, B. Monzavi-Karbassi, R.A. Hedges, L.J. Rogers, S.A. Kadlubar, T. Kieber-Emmons, Adipocyte hypoxia promotes epithelial-mesenchymal transition-related gene expression and estrogen receptor-negative phenotype in breast cancer cells. Oncol. Rep. 33, 2689–2694 (2015)PubMedPubMedCentralCrossRef
95.
C. Wang, C. Gao, K. Meng, H. Qiao, Y. Wang, Human adipocytes stimulate invasion of breast cancer MCF-7 cells by secreting IGFBP-2. PLoS One 10, e0119348 (2015)PubMedPubMedCentralCrossRef
96.
X. Catteau, P. Simon, J.-C. NoëL, Stromal expression of matrix metalloproteinase 2 in cancer-associated fibroblasts is strongly related to human epidermal growth factor receptor 2 status in invasive breast carcinoma. Mol. Clin. Oncol. 4, 375–378 (2016)PubMedCrossRef
97.
V. D’Esposito, F. Passaretti, A. Hammarstedt, D. Liguoro, D. Terracciano, G. Molea, L. Canta, C. Miele, U. Smith, F. Beguinot, P. Formisano, Adipocyte-released insulin-like growth factor-1 is regulated by glucose and fatty acids and controls breast cancer cell growth in vitro. Diabetologia 55, 2811–2822 (2012)PubMedPubMedCentralCrossRef
98.
L. Bochet, A. Meulle, S. Imbert, B. Salles, P. Valet, C. Muller, Cancer-associated adipocytes promotes breast tumor radioresistance. Biochem. Biophys. Res. Commun. 411, 102–106 (2011)PubMedCrossRef
99.
K. Fujisaki, H. Fujimoto, T. Sangai, T. Nagashima, M. Sakakibara, N. Shiina, M. Kuroda, Y. Aoyagi, M. Miyazaki, Cancer-mediated adipose reversion promotes cancer cell migration via IL-6 and MCP-1. Breast Cancer Res. Treat. 150, 255–263 (2015)PubMedCrossRef
100.
V. D'Esposito, D. Liguoro, M.R. Ambrosio, F. Collina, M. Cantile, R. Spinelli, G.A. Raciti, C. Miele, R. Valentino, P. Campiglia, M. De Laurentiis, M. Di Bonito, G. Botti, R. Franco, F. Beguinot, P. Formisano, Adipose microenvironment promotes triple negative breast cancer cell invasiveness and dissemination by producing CCL5. Oncotarget 7, 24495–24509 (2016)
101.
M.N. Duong, A. Cleret, E.L. Matera, K. Chettab, D. Mathe, S. Valsesia-Wittmann, B. Clemenceau, C. Dumontet, Adipose cells promote resistance of breast cancer cells to trastuzumab-mediated antibody-dependent cellular cytotoxicity. Breast Cancer Res. 17, 57 (2015)PubMedPubMedCentralCrossRef
102.
D. Katoh, M. Nishizuka, S. Osada, M. Imagawa, Fad104, a positive regulator of adipocyte differentiation, suppresses invasion and metastasis of melanoma cells by inhibition of STAT3 activity. PLoS One 10, e0117197 (2015)PubMedPubMedCentralCrossRef
103.
A.L. Ribeiro, C. Kaid, P.B.G. Silva, B.A. Cortez, O.K. Okamoto, Inhibition of lysyl oxidases impairs migration and angiogenic properties of tumor-associated pericytes. Stem Cells Int. 4972078, 2017 (2017)
104.
K. Hosaka, Y. Yang, T. Seki, C. Fischer, O. Dubey, E. Fredlund, J. Hartman, P. Religa, H. Morikawa, Y. Ishii, M. Sasahara, O. Larsson, G. Cossu, R. Cao, S. Lim, Y. Cao, Pericyte–fibroblast transition promotes tumor growth and metastasis. Proc. Natl. Acad. Sci. U. S. A. 113, E5618–E5627 (2016)PubMedPubMedCentralCrossRef
105.
J. Hong, N.P. Tobin, H. Rundqvist, T. Li, M. Lavergne, Y. García-Ibáñez, H. Qin, J. Paulsson, M. Zeitelhofer, M.Z. Adzemovic, I. Nilsson, P. Roswall, J. Hartman, R.S. Johnson, A. Östman, J. Bergh, M. Poljakovic, G. Genové, Role of tumor pericytes in the recruitment of myeloid-derived suppressor cells. J. Natl. Cancer Inst. 107, djv209 (2015)PubMedCrossRef
106.
J.H. Trevino-Villarreal, R. Sepulveda, D.A. Cotanche, R.A. Rogers, Effect of pericytes on epithelial-to-mesenchymal transition in melanoma. J. Clin. Oncol. 30, 84–84 (2012)CrossRef
107.
M. Teichert, L. Milde, A. Holm, L. Stanicek, N. Gengenbacher, S. Savant, T. Ruckdeschel, Z. Hasanov, K. Srivastava, J. Hu, S. Hertel, A. Bartol, K. Schlereth, H.G. Augustin, Pericyte-expressed Tie2 controls angiogenesis and vessel maturation. Nat. Commun. 8, 16106 (2017)PubMedPubMedCentralCrossRef
108.
L.E. Reynolds, G. D'Amico, T. Lechertier, A. Papachristodoulou, J.M. Muñoz-Félix, A. De Arcangelis, M. Baker, B. Serrels, K.M. Hodivala-Dilke, Dual role of pericyte α6β1-integrin in tumour blood vessels. J. Cell Sci. 130, 1583–1595 (2017)
109.
D. Sinha, L. Chong, J. George, H. Schlüter, S. Mönchgesang, S. Mills, J. Li, C. Parish, D. Bowtell, P. Kaur, Pericytes promote malignant ovarian cancer progression in mice and predict poor prognosis in serous ovarian cancer patients. Clin. Cancer Res. 22, 1813–1824 (2015)PubMedCrossRef
110.
A. Chavez-Gonzalez, B. Bakhshinejad, K. Pakravan, M.L. Guzman, S. Babashah, Novel strategies for targeting leukemia stem cells: Sounding the death knell for blood cancer. Cell. Oncol. 40, 1–20 (2017)CrossRef
111.
B. Leyh, A. Dittmer, T. Lange, J.W. Martens, J. Dittmer, Stromal cells promote anti-estrogen resistance of breast cancer cells through an insulin-like growth factor binding protein 5 (IGFBP5)/B-cell leukemia/lymphoma 3 (Bcl-3) axis. Oncotarget 6, 39307–39328 (2015)PubMedPubMedCentralCrossRef
112.
R.D. Guardia, B. Lopez-Millan, J.R. Lavoie, C. Bueno, J. Castaño, M. Gómez-Casares, S. Vives, L. Palomo, M. Juan, J. Delgado, M.L. Blanco, J. Nomdedeu, A. Chaparro, J.L. Fuster, E. Anguita, M. Rosu-Myles, P. Menéndez, Detailed characterization of mesenchymal stem/stromal cells from a large cohort of AML patients demonstrates a definitive link to treatment outcomes. Stem Cell Reports 8, 1573–1586 (2017)CrossRef
113.
K.M. McAndrews, D.J. McGrail, N. Ravikumar, M.R. Dawson, Mesenchymal stem cells induce directional migration of invasive breast cancer cells through TGF-β. Sci. Rep. 5, 16941 (2015)
114.
H.H. Wang, Y.L. Cui, N.G. Zaorsky, J. Lan, L. Deng, X.L. Zeng, Z.Q. Wu, Z. Tao, W.H. Guo, Q.X. Wang, L.J. Zhao, Z.Y. Yuan, Y. Lu, P. Wang, M.B. Meng, Mesenchymal stem cells generate pericytes to promote tumor recurrence via vasculogenesis after stereotactic body radiation therapy. Cancer Lett. 375, 349–359 (2016)
115.
T.L. Watts, R. Cui, P. Szaniszlo, V.A. Resto, D.W. Powell, I.V. Pinchuk, PDGF-AA mediates mesenchymal stromal cell chemotaxis to the head and neck squamous cell carcinoma tumor microenvironment. J. Transl. Med. 14, 337 (2016)PubMedPubMedCentralCrossRef
116.
F. Ma, D. Chen, F. Chen, Y. Chi, Z. Han, X. Feng, X. Li, Z. Han, Human umbilical cord mesenchymal stem cells promote breast cancer metastasis by interleukin-8- and interleukin-6-dependent induction of CD44+/CD24- cells. Cell Transplant. 24, 2585–2599 (2015)PubMedCrossRef
117.
P.F. Yu, Y. Huang, C.L. Xu, L.Y. Lin, Y.Y. Han, W.H. Sun, G.H. Hu, A.B. Rabson, Y. Wang, Y.F. Shi, Downregulation of CXCL12 in mesenchymal stromal cells by TGFβ promotes breast cancer metastasis. Oncogene 36, 840–849 (2017)PubMedCrossRef
118.
119.
A. Scholz, P.N. Harter, S. Cremer, B.H. Yalcin, S. Gurnik, M. Yamaji, M. Di Tacchio, K. Sommer, P. Baumgarten, O. Bahr, J.P. Steinbach, J. Trojan, M. Glas, U. Herrlinger, D. Krex, M. Meinhardt, A. Weyerbrock, M. Timmer, R. Goldbrunner, M. Deckert, C. Braun, J. Schittenhelm, J.T. Frueh, E. Ullrich, M. Mittelbronn, K.H. Plate, Y. Reiss, Endothelial cell-derived angiopoietin-2 is a therapeutic target in treatment-naive and bevacizumab-resistant glioblastoma. EMBO Mol. Med. 8, 39–57 (2016)PubMedCrossRef
120.
M.-Y. Hsu, M.H. Yang, C.I. Schnegg, S. Hwang, B. Ryu, R.M. Alani, Notch3 signaling-mediated melanoma–endothelial crosstalk regulates melanoma stem-like cell homeostasis and niche morphogenesis. Lab. Invest. 97, 725–736 (2017)PubMedPubMedCentralCrossRef
121.
E. Wieland, J. Rodriguez-Vita, S.S. Liebler, C. Mogler, I. Moll, S.E. Herberich, E. Espinet, E. Herpel, A. Menuchin, J. Chang-Claude, M. Hoffmeister, C. Gebhardt, H. Brenner, A. Trumpp, C.W. Siebel, M. Hecker, J. Utikal, D. Sprinzak, A. Fischer, Endothelial Notch1 activity facilitates metastasis. Cancer Cell 31, 355–367 (2017)PubMedCrossRef
122.
B. Balinisteanu, A.M. Cimpean, E. Melnic, M. Coculescu, R.A. Ceausu, M. Raica, Crosstalk between tumor blood vessels heterogeneity and hormonal profile of pituitary adenomas: Evidence and controversies. Anticancer Res. 34, 5413–5420 (2014)PubMed
123.
P. Ghiabi, J. Jiang, J. Pasquier, M. Maleki, N. Abu-Kaoud, N. Halabi, B.S. Guerrouahen, S. Rafii, A. Rafii, Breast cancer cells promote a notch-dependent mesenchymal phenotype in endothelial cells participating to a pro-tumoral niche. J. Transl. Med. 13, 27 (2015)PubMedPubMedCentralCrossRef
124.
R. Wilson, C. Espinosa-Diez, N. Kanner, N. Chatterjee, R. Ruhl, C. Hipfinger, S.J. Advani, J. Li, O.F. Khan, A. Franovic, S.M. Weis, S. Kumar, L.M. Coussens, D.G. Anderson, C.C. Chen, D.A. Cheresh, S. Anand, MicroRNA regulation of endothelial TREX1 reprograms the tumour microenvironment. Nat. Commun. 7, 13597 (2016)PubMedPubMedCentralCrossRef
125.
K. Gupta, R. Metgud, J. Gupta, Evaluation of stromal myofibroblasts in oral leukoplakia, oral submucous fibrosis, and oral squamous cell carcinoma - an immunohistochemical study. J. Cancer Res. Ther. 11, 893–898 (2015)PubMedCrossRef
126.
M. Chaudhary, A.R. Gadbail, G. Vidhale, M.P. Mankar, S.M. Gondivkar, M. Gawande, S. Patil, Comparison of myofibroblasts expression in oral squamous cell carcinoma, verrucous carcinoma, high risk epithelial dysplasia, low risk epithelial dysplasia and normal oral mucosa. Head Neck Pathol. 6, 305–313 (2012)PubMedPubMedCentralCrossRef
127.
M. Mehdipour, M. Shahidi, S. Manifar, S. Jafari, F. Mashhadi Abbas, M. Barati, H. Mortazavi, M. Shirkhoda, A. Farzanegan, Z. Elmi Rankohi, Diagnostic and prognostic relevance of salivary microRNA-21, −125a, −31 and -200a levels in patients with oral lichen planus - a short report. Cell. Oncol. 41, 329–334 (2018)CrossRef
128.
R. Tamamura, H. Nagatsuka, C.H. Siar, N. Katase, I. Naito, Y. Sado, N. Nagai, Comparative analysis of basal lamina type IV collagen α chains, matrix metalloproteinases-2 and -9 expressions in oral dysplasia and invasive carcinoma. Acta Histochem. 115, 113–119 (2013)PubMedCrossRef
129.
H.-X. Fan, H.-X. Li, D. Chen, Z.-X. Gao, J.-H. Zheng, Changes in the expression of MMP2, MMP9, and ColIV in stromal cells in oral squamous tongue cell carcinoma: Relationships and prognostic implications. J. Exp. Clin. Cancer Res. 31, 90 (2012)PubMedPubMedCentralCrossRef
130.
P. Le Bars, P. Piloquet, A. Daniel, B. Giumelli, Immunohistochemical localization of type IV collagen and laminin (alpha1) in denture stomatitis. J. Oral Pathol. Med. 30, 98–103 (2001)PubMedCrossRef
131.
F.B. Galateau-Salle, R.E. Luna, K. Horiba, M.N. Sheppard, T. Hayashi, M.V. Fleming, T.V. Colby, W. Bennett, C.C. Harris, W.G. Stetler-Stevenson, L. Liotta, V.J. Ferrans, W.D. Travis, Matrix metalloproteinases and tissue inhibitors of metalloproteinases in bronchial squamous preinvasive lesions. Hum. Pathol. 31, 296–305 (2000)PubMedCrossRef
132.
M. Sathyakumar, G. Sriram, T.R. Saraswathi, B. Sivapathasundharam, Immunohistochemical evaluation of mast cells and vascular endothelial proliferation in oral precancerous lesion-leukoplakia. J. Oral Maxillofac. Pathol. 16, 343–348 (2012)PubMedPubMedCentralCrossRef
133.
S. Ramsridhar, M. Narasimhan, Immunohistochemical evaluation of mast cells in leukoplakia and oral squamous cell carcinoma. J. Clin. Diagn. Res. 10, ZC100–ZC103 (2016)PubMedPubMedCentral
134.
M. Kinra, K. Ramalingam, A. Sarkar, F. Rehman, K.L. Girish, Comparison of mast cell count and mast cell density in normal mucosa, oral leukoplakia, oral lichen planus, oral submucous fibrosis and oral squamous cell carcinoma–a study on 50cases. JPSI 1, 4–11 (2012)
135.
S. Nayak, M.M. Goel, A. Makker, V. Bhatia, S. Chandra, S. Kumar, S.P. Agarwal, Fibroblast growth factor (FGF-2) and its receptors FGFR-2 and FGFR-3 may be putative biomarkers of malignant transformation of potentially malignant oral lesions into oral squamous cell carcinoma. PLoS One 10, e0138801 (2015)PubMedPubMedCentralCrossRef
136.
137.
S.P. Kerkar, N.P. Restifo, Cellular constituents of immune escape within the tumor microenvironment. Cancer Res. 72, 3125–3130 (2012)PubMedCrossRef
138.
H. Qin, C. Zhao, Y. Sun, J. Ren, X. Qu, Metallo-supramolecular complexes enantioselectively eradicate cancer stem cells in vivo. J. Am. Chem. Soc. 139, 16201–16209 (2017)PubMedCrossRef
139.
V. Pautu, D. Leonetti, E. Lepeltier, N. Clere, C. Passirani, Nanomedicine as a potent strategy in melanoma tumor microenvironment. Pharmacol. Res. 126, 31–53 (2017)PubMedCrossRef
140.
G. Valenti, H.M. Quinn, G.J.J.E. Heynen, L. Lan, J.D. Holland, R. Vogel, A. Wulf-Goldenberg, W. Birchmeier, Cancer stem cells regulate cancer-associated fibroblasts via activation of hedgehog signaling in mammary gland tumors. Cancer Res. 77, 2134–2147 (2017)PubMedCrossRef
141.
C. Zang, J. Eucker, P. Habbel, C. Neumann, C.-O. Schulz, N. Bangemann, L. Kissner, H. Riess, H. Liu, Targeting multiple tyrosine kinase receptors with Dovitinib blocks invasion and the interaction between tumor cells and cancer-associated fibroblasts in breast cancer. Cell Cycle 14, 1291–1299 (2015)PubMedPubMedCentralCrossRef
142.
F. Mpekris, P. Papageorgis, C. Polydorou, C. Voutouri, M. Kalli, A.P. Pirentis, T. Stylianopoulos, Sonic-hedgehog pathway inhibition normalizes desmoplastic tumor microenvironment to improve chemo- and nanotherapy. J. Control. Release 261, 105–112 (2017)PubMedPubMedCentralCrossRef
143.
Y. Du, Q. Long, L.I.N. Zhang, Y. Shi, X. Liu, X. Li, B.I.N. Guan, Y. Tian, X. Wang, L.E.I. Li, D. He, Curcumin inhibits cancer-associated fibroblast-driven prostate cancer invasion through MAOA/mTOR/HIF-1α signaling. Int. J. Oncol. 47, 2064–2072 (2015)PubMedPubMedCentralCrossRef
144.
K. Li, H. Kang, Y. Wang, T. Hai, G. Rong, H. Sun, Letrozole-induced functional changes in carcinoma-associated fibroblasts and their influence on breast cancer cell biology. Med. Oncol. 33, 64 (2016)PubMedCrossRef
145.
K.P.L. Fabian, N. Chi-Sabins, J.L. Taylor, R. Fecek, A. Weinstein, W.J. Storkus, Therapeutic efficacy of combined vaccination against tumor pericyte-associated antigens DLK1 and DLK2 in mice. Oncoimmunology 6, e1290035 (2017)PubMedPubMedCentralCrossRef
146.
C. Wang, Y. Li, H. Chen, J. Zhang, J. Zhang, T. Qin, C. Duan, X. Chen, Y. Liu, X. Zhou, J. Yang, Inhibition of CYP4A by a novel flavonoid FLA-16 prolongs survival and normalizes tumor vasculature in glioma. Cancer Lett. 402, 131–141 (2017)PubMedCrossRef
147.
Q. Zhou, Y. Zhou, X. Liu, Y. Shen, GDC-0449 improves the antitumor activity of nano-doxorubicin in pancreatic cancer in a fibroblast-enriched microenvironment. Sci. Rep. 7, 13379 (2017)
148.
C.J. Hanley, M. Mellone, K. Ford, S.M. Thirdborough, T. Mellows, S.J. Frampton, D.M. Smith, E. Harden, C. Szyndralewiez, M. Bullock, F. Noble, K.A. Moutasim, E.V. King, P. Vijayanand, A.H. Mirnezami, T.J. Underwood, C.H. Ottensmeier, G.J. Thomas, Targeting the myofibroblastic cancer-associated fibroblast phenotype through inhibition of NOX4. J. Natl. Cancer Inst. 110, 109–120 (2018). https://​doi.​org/​10.​1093/​jnci/​djx121 CrossRef
149.
M. Gabasa, R. Ikemori, F. Hilberg, N. Reguart, J. Alcaraz, Nintedanib selectively inhibits the activation and tumour-promoting effects of fibroblasts from lung adenocarcinoma patients. Br. J. Cancer 117, 1128–1138 (2017)PubMedPubMedCentralCrossRef
150.
Y. Wei, T.J. Kim, D.H. Peng, D. Duan, D.L. Gibbons, M. Yamauchi, J.R. Jackson, C.J. Le Saux, C. Calhoun, J. Peters, R. Derynck, B.J. Backes, H.A. Chapman, Fibroblast-specific inhibition of TGF-β1 signaling attenuates lung and tumor fibrosis. J. Clin. Invest. 127, 3675–3688 (2017)PubMedPubMedCentralCrossRef
151.
M. Chen, X. Lei, C. Shi, M. Huang, X. Li, B. Wu, Z. Li, W. Han, B. Du, J. Hu, Q. Nie, W. Mai, N. Ma, N. Xu, X. Zhang, C. Fan, A. Hong, M. Xia, L. Luo, A. Ma, H. Li, Q. Yu, H. Chen, D. Zhang, W. Ye, Pericyte-targeting prodrug overcomes tumor resistance to vascular disrupting agents. J. Clin. Invest. 127, 3689–3701 (2017)PubMedPubMedCentralCrossRef
Metadata
Title
Mutual concessions and compromises between stromal cells and cancer cells: driving tumor development and drug resistance
Authors
Pritish Nilendu
Sachin C. Sarode
Devashree Jahagirdar
Ishita Tandon
Shankargouda Patil
Gargi S. Sarode
Jayanta K. Pal
Nilesh Kumar Sharma
Publication date
01-08-2018
Publisher
Springer Netherlands
Published in
Cellular Oncology / Issue 4/2018
Print ISSN: 2211-3428
Electronic ISSN: 2211-3436
DOI
https://doi.org/10.1007/s13402-018-0388-2

Other articles of this Issue 4/2018

Cellular Oncology 4/2018 Go to the issue

Original Paper

Cancer-associated fibroblasts affect breast cancer cell gene expression, invasion and angiogenesis

Original Paper

Potential of the dual mTOR kinase inhibitor AZD2014 to overcome paclitaxel resistance in anaplastic thyroid carcinoma

Original Paper

Identification of biomarkers associated with partial epithelial to mesenchymal transition in the secretome of slug over-expressing hepatocellular carcinoma cells

Original Paper

Patched-2 functions to limit Patched-1 deficient skin cancer growth

Report

AAA+ ATPases Reptin and Pontin as potential diagnostic and prognostic biomarkers in salivary gland cancer - a short report

Original Paper

Identification of subsets of actionable genetic alterations in KRAS-mutant lung cancers using association rule mining
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits